Cite

HARVARD Citation

    Wolfe, Z. et al. (2022). Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. Melanoma research. 32 (4), pp. 295-298. [Online]. 
  
Back to record